merged_china-pharma-drugs.txt
<question_number>1</question_number>  
<answer>N/A</answer>  

<question_number>2</question_number>  
<answer>N/A</answer>  

<question_number>3</question_number>  
<answer>N/A</answer>  

<question_number>4</question_number>  
<answer>N/A</answer>  

<question_number>5</question_number>  
<answer>N/A</answer>  

<question_number>6</question_number>  
<answer>N/A</answer>  

<question_number>7</question_number>  
<answer>Doctors and hospital leaders proposed allowing patients to choose original branded drugs even if not on the approved procurement list, with insurance reimbursement adjusted based on whether the drug was original or generic.</answer>  

<question_number>8</question_number>  
<answer>N/A</answer>  

<question_number>9</question_number>  
<answer>N/A</answer>  

<question_number>10</question_number>  
<answer>N/A</answer>  

<question_number>11</question_number>  
<answer>China's National Healthcare Security Administration</answer>  

<question_number>12</question_number>  
<answer>Xia Zhimin</answer>  

<question_number>13</question_number>  
<answer>Zheng Minhua</answer>  

<question_number>14</question_number>  
<answer>Volume-based procurement</answer>  

<question_number>15</question_number>  
<answer>The former editor at a leading online health platform</answer>  

<question_number>16</question_number>  
<answer>The policy is the central bidding system that favors cheaper drugs, which in most cases have been generics made by Chinese companies.</answer>  

<question_number>17</question_number>  
<answer>Lu Changlin</answer>  

<question_number>18</question_number>  
<answer>Beijing's government</answer>  

<question_number>19</question_number>  
<answer>Private clinics</answer>  

<question_number>20</question_number>  
<answer>Xia Zhimin</answer>